2 news items
InflaRx Hosts R&D Event Highlighting the Promise of INF904
IFRX
5 Jun 24
leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
IFRX
8 May 24
and the opportunity, the role of C5aR in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) and C5a/C5aR signaling in human
- Prev
- 1
- Next